Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Seeks PMA Requirements For More Pre-Amendment Devices

This article was originally published in The Gray Sheet

Executive Summary

FDA is proposing to require pre-market approval applications for three class III, pre-amendment device types in the cardiovascular and neurologic device spaces.

You may also be interested in...



Dueling Journal Commentaries Revisit FDA Approval of Abiomed's Impella

The pieces in JAMA Cardiology consider the merits of FDA's "515 Program Initiative" to classify preamendment devices and its application to a minimally invasive ventricular assist device.

Class Act: Status Of CDRH’s 515 Initiative

Chart updating FDA’s progress and decisions in classifying the final set of preamendment devices.

Regulatory News In Brief

President Obama signs FDA user fee bill. FDA issues rules requiring PMAs for two pre-amendment devices. More regulatory news.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030433

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel